{
    "clinical_study": {
        "@rank": "10031", 
        "arm_group": {
            "arm_group_label": "Radiofrequency ablation", 
            "arm_group_type": "Experimental", 
            "description": "To study the safety and effectiveness of radiofrequency ablation (RFA) using the HALO ablation system in completely eradicating the diseased epithelium in patients with ESCN"
        }, 
        "brief_summary": {
            "textblock": "90% of treated patients with MGIN, HGIN or flat-type early SCCA of the esophagus will have\n      complete eradication of squamous histological abnormalities (MGIN and worse) within the\n      treated area at 12 months after initial treatment session (defined as a complete response\n      (CR) for MGIN, HGIN, and SCCA)"
        }, 
        "brief_title": "Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "ESOPHAGEAL SQUAMOUS CELL CARCINOMA", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Squamous Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "In a patient population with a histopathological diagnosis of moderate-grade\n      intra-epithelial neoplasia (MGIN), high-grade intra-epithelial neoplasia (HGIN) and/or early\n      flat-type SCCA of the esophagus, evaluate the safety and effectiveness of radiofrequency\n      ablation (RFA) using the HALO ablation system in completely eradicating the diseased\n      epithelium"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject is 18-80 years of age, inclusive\n\n          2. Subject meets at least one of the following inclusion criteria:\n\n               1. Within the last 3 months, subject demonstrated a new diagnosis or a reconfirmed\n                  diagnosis of squamous MGIN and/or HGIN of the esophagus, or...\n\n               2. within the last 3 months, subject demonstrated a new diagnosis of a flat-type\n                  (type 0-IIb) SCCA (G1/G2 only)\n\n          3. On endoscopic examination, subject has at least one USL that measures at least 3 cm\n             in at least one dimension and has MGIN or worse (MGIN+) on biopsy\n\n          4. The maximum allowable linear length of \"USL-bearing esophagus\" is 12 cm\n\n          5. Baseline EUS (all patients) shows no exclusionary findings for the trial\n\n          6. CT scan of chest and upper third of the abdomen (all HGIN and SCCA patients) shows no\n             exclusionary findings for the trial\n\n          7. Subject is not pregnant nor has plans to become pregnant in the ensuing 12 months\n             (confirmation of non-pregnant status in women of child-bearing age and ability\n             required with urine or blood test)\n\n          8. Subject is eligible for treatment and follow-up endoscopy and biopsy as required by\n             the protocol\n\n          9. The subject is willing to provide written, informed consent to participate in this\n             clinical study and understands the responsibilities of trial participation\n\n        Exclusion Criteria:\n\n        the Eligibility CRF.\n\n          1. Esophageal stricture preventing passage of a therapeutic endoscope\n\n          2. Any prior endoscopic resection\n\n          3. Any esophageal dilation in the past 12 months\n\n          4. Any history of a non-squamous cell cancer of the esophagus, or any history of a\n             squamous cell cancer of the esophagus (any stage) prior to 3 months before screening\n             for this trial\n\n          5. Any N or M positive status, if patient has a present diagnosis of esophageal SCCA\n\n          6. Any previous ablative therapy within the esophagus (photodynamic therapy, multipolar\n             electrical coagulation, argon plasma coagulation, laser treatment, or other) or any\n             radiation therapy to the esophagus.\n\n          7. Any previous esophageal surgery, except fundoplication without complications (i.e. no\n             slippage, dysphagia, etc)\n\n          8. Evidence of esophageal varices detected within last 6 months or at initial RFA\n             procedure\n\n          9. Evidence of eosinophilic esophagitis on endoscopy and/or histology\n\n         10. Report of uncontrolled coagulopathy with international normalized ratio (INR) > 2 or\n             platelet count <75,000 platelets per \u00b5L (note: a complete blood count is not required\n             for all subjects in this study)\n\n         11. Subject is using aspirin, clopidogrel, or non-steroidal anti-inflammatory drugs that\n             can not be discontinued 7 days before and after therapeutic sessions\n\n         12. Subject has a known history of unresolved drug or alcohol dependency that would limit\n             ability to comprehend or follow instructions related to informed consent,\n             post-treatment instructions, or follow-up guidelines\n\n         13. Subject has an implantable pacing device (examples; AICD, neurostimulator, cardiac\n             pacemaker) and has not received clearance for enrollment in this study by specialist\n             responsible for the pacing device\n\n         14. Subject suffers from psychiatric or other illness deemed by the investigator as an\n             inability to comply with protocol\n\n         15. Subject has life expectancy less than 2 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047305", 
            "org_study_id": "B300"
        }, 
        "intervention": {
            "arm_group_label": "Radiofrequency ablation", 
            "description": "Patients with a histopathological diagnosis of moderate-grade intra-epithelial neoplasia (MGIN), high-grade intra-epithelial neoplasia (HGIN) and/or early flat-type SCCA of the esophagus, are treated with radiofrequency ablation, with repeat endoscopy and follow-up treatment at 3 month intervals.", 
            "intervention_name": "Radiofrequency Ablation", 
            "intervention_type": "Device", 
            "other_name": [
                "RFA", 
                "Barrx ablation system", 
                "HALO ablation system"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ESCN", 
            "RFA"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100021"
                }, 
                "name": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-center Trial of Endoscopic Radiofrequency Ablation of Moderate and High-grade Intra-epithelial Squamous Neoplasia and Early Flat-type Squamous Cell Carcinoma Using the HALO Ablation System", 
        "overall_official": {
            "affiliation": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College", 
            "last_name": "Guiqi Wang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "China: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The percentage of subjects demonstrating complete response (CR) defined as complete histological clearance of MGIN, HGIN and SCCA in the TA at 12 months after the initial ablation procedure", 
            "measure": "Complete response", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047305"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Subject discomfort 0-14 days post-procedure as evidenced by patient diary recordings, and adverse event incidence", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "source": "Covidien, GI Solutions", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Covidien, GI Solutions", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2009", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}